Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo

Journal of Nuclear Medicine

Volumn 39, Issue 6, 1998, Pages 996-1001

  Larisch, Rolf ^a   Schulte, Klaus Werner ^b   Vosberg, Henning ^b   Ruzicka, Thomas ^b   Müller Gärtner, Hans Wilhelm ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

Dopamine; Iodine 123 iodobenzamide; Melanin; Melanoma; Tumor imaging

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; IODINE 123; IODOBENZAMIDE I 123; MELANIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IN VIVO STUDY; MALE; MELANOGENESIS; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; CONTRAST MEDIA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MELANINS; MELANOMA; MELANOMA, AMELANOTIC; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLIDINES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031811338     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Drake LA, Ceilley RI, Cornelison RL. Guidelines of care for malignant melanoma. J Am Acad Dermatol 1993;28:638-641.
2. 123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results. Eur J Nucl Med 1993;20:238-243.
3. Michelot JM, Moreau MFC, Veyre AJ, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl-4-iodo? benzamide). J Nucl Med 1993;34:1260-1266.
4. Maffioli LS, Mascheroni L, Clemente C, Baldini M, Castellani MR. Iodine-123-IBZM uptake in metastatic melanoma. J Nucl Biol Med 1993;37:18-20.
5. Maffioli L, Mascheroni L, Mongioj V, et al. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 1994;35:1741-1747.
6. 123I-jodbenzofuran beim malignen melanom. Nuklearmedizin 1995;34: 146-150.
7. Boeni R, Steinert H, Hueh Boeni RA, et al. Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzfurans with melanin. Dermatology 1996;193:198-202.
8. Bruecke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatrie disorders. J Cereb Blood Flow Metab 1991;11:220-228.
9. 123I iodobenzamide SPECT in 6 healthy volunteers. J Nucl Med 1991;32: 1078.
10. 123,131I]iodobenzamides by animal and cell culture studies. J Lab Comp Radiopharm 1995;37:260-262.
11. Tajima S, Ura-Ishiko A, Hayashi A. Melanogenesis, biosynthetic phenotype of fibronectin and collagen, and migrating activity in cloned B16 mouse melanoma cells. J Dermatol Sci 1996;12:24-30.
12. Jiang J, Sharma SD, Nakamura S, et al. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995;8:314-323.
13. Kung HF, Pan S, Kung MP, et al. in vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989;30:88-92.
14. Eary JF, Schroff RW, Abrams PG, et al. Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med 1989;30:25-32.
15. Taylor A Jr., Milton W, Eyre H, et al. Radioimmunodetection of human melanoma with indium-111-labeled monoclonal antibody. J Nucl Med 1988;29:329-337.
16. Boeni R, Huch Boeni RA, Steinert HC, Dummer R, Burg G, von Schulthess GK. Antimelanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Dermatology 1995;191:119-123.
17. Siccardi AG. Tumor immunoscintigraphy by means of radiolabeled monoclonal antibodies: multicenter studies of the Italian National Research Council-Special Project "Biomedical Engineering" Cancer Res 1990;50(suppl 3):899s-903s.
18. Steinert HC, Huch Boeni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-709.
19. Patton DD. Cost-effectiveness in nuclear medicine. Semin Nucl Med 1993;23:9-30.